Overview
The study is designed to validate efficacy and long term safety of PP405.
Description
Participants will initially be randomized 1:1 to PP405 or vehicle and complete a 24 week double blinded treatment period. At Week 24, the PP405 group will continue PP405 treatment, and the vehicle group will be re-randomized 1:1 to PP405 or vehicle for the double-blind long term safety extension period through study week 52.
Eligibility
Inclusion Criteria:
- Males (assigned at birth) aged 18 to 55 years, inclusive at time of consent.
- Able and willing to provide written informed consent
- Must have been experiencing Androgenetic Alopecia (AGA) for at least 6 months prior to screening.
- Have a modified Norwood-Hamilton score of Type IV or Type V
- Agree to comply with protocol procedures
Exclusion Criteria:
- Concomitant diagnosis of non-AGA forms of alopecia.
- Use of other hair loss treatments within periods specified in protocol.
- Use of excluded medications and procedures as specified in protocol.
- Diagnosis of other medical conditions as specified in protocol.
- Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results.
